Desidustat Tablets Being Granted an Approval for Drug Clinical Trial

Company News

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that Desidustat Tablets of the Group licensed in from Cadila Healthcare Limited (“Zydus”) on 20 January 2020, has been granted an approval for drug clinical trial issued on 18 January 2021 from the National Medical Products Administration of the People’s Republic of China and agreed to carry out clinical trials for indication of anemia (including dialysis and non-dialysis patients) caused by chronic kidney disease (CKD) .

Desidustat Tablets are novel oral Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHI) for treating anemia in CKD patients. 

The Group is currently actively preparing for initiating the relevant clinical trials.